Project company

Project company Laxxon Medical achieves major milestone


Xlife Sciences AG / Keyword(s): Miscellaneous
Project company Laxxon Medical achieves major milestone
26.09.2022 / 07:00 CET/CEST

Xlife Sciences AG (SIX: XLS) is pleased to announce that its project company Laxxon Medical has been granted US Patent 11,419,824 B2 for the controlled delivery of one or more active pharmaceutical ingredients in a drug delivery system. drugs via oral dosage forms by the United States Patent and Trademark Office (USPTO).

The patent covers the sequential release of two or more active pharmaceutical ingredients in a 3D-printed drug delivery system. Multi-drug drugs and 3D printing are fierce emerging players in the pharmaceutical industry. These new technologies are pushing the boundaries of medicine and defining the next generation of healthcare; individualized and personalized medicines play an increasingly important role in the future of healthcare. Laxxon Medical’s patent portfolio includes over 150 patents, licensed patents and patent applications, including over 3,000 patent claims. The portfolio includes patents and applications relating to methods and devices for drug delivery systems.

Oliver R. Baumann, CEO of Xlife Sciences, commented: “This patent establishes Laxxon Medical as a market leader in 3D printed pharmaceuticals. Congratulations to the dedicated team at Laxxon for reaching this major milestone in the company’s development strategy”.

Laxxon Medical’s Drug Delivery System (DDS) is a 3D screen-printed oral, intra, or transdermal dosage that, due to the precise placement of Active Pharmaceutical Ingredients (APIs) within the system, allows for personalized administration and release profile of one or more therapeutic applications in a human or animal patient. DDS optimizes pharmacokinetics and pharmacodynamics, producing optimal clinical outcomes and fewer side effects, while requiring less API than conventional methods of drug delivery systems. Additionally, Laxxon Medical’s DDS is not limited to any particular API, enabling mass application among pharmaceutical drug therapies.

Financial calendar

Half-year report 2022 September 28, 2022


Information for journalists: IRF Reputation AG, Valentin Handschin, [email protected]

Investor information: Xlife Sciences AG, Dennis Lennartz, [email protected]

Xlife Sciences SA

Talacker 35

8001 Zürich

Telephone: 0041 44 385 84 60

Email: [email protected]

The Internet:

ISIN: CH0461929603


Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as an incubator and accelerator on the valuable development and commercialization of promising research projects from universities and other research institutes in the life sciences sector, with the aim of provide solutions to unmet medical needs and improved quality of life. The aim is to link research and development to health markets. Xlife Sciences brings carefully selected projects in the four areas of technology platforms, biotechnology/therapeutics, medical technology and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit


Some of the information in this press release contains forward-looking statements. Readers are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements due to a variety of factors. Xlife Sciences assumes no obligation to publicly update or revise any forward-looking statements.

End of press release

Source link